{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:26:34Z","timestamp":1792207594088,"version":"4.4.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed\/refractory marginal zone lymphoma (R\/R MZL), with a favorable safety\/tolerability profile. Presented here, is the final analysis of MAGNOLIA, performed to characterize the durability of response and longer-term safety and tolerability. Zanubrutinib (160\u00a0mg twice daily) was evaluated in 68 patients with R\/R MZL who had received at least 1 anti-CD20\u2013directed regimen. The primary end point was independent review committee (IRC)-assessed ORR. Secondary end points included investigator-assessed ORR, duration of response (DOR), progression-free survival (PFS), overall survival (OS), health-related quality of life, safety, and tolerability. With a median follow-up of 27.4\u00a0months, the IRC-assessed ORR was 68.2% (95% confidence interval [CI], 55.6-79.1), with a 24-month DOR event-free rate of 72.9% (95%\u00a0CI, 54.4-84.9). PFS and OS at 24\u00a0months were 70.9% (95%\u00a0CI, 57.2-81.0) and 85.9% (95%\u00a0CI, 74.7-92.4), respectively. The zanubrutinib safety profile was consistent with the primary analysis, with no new safety signals observed. Atrial fibrillation\/flutter (n\u00a0= 2 [2.9%]) and hypertension (n\u00a0= 3 [4.4%]) were uncommon. Neutropenia (n\u00a0= 8 [11.8%]) was the most common grade \u22653 adverse event. In this final analysis of MAGNOLIA, zanubrutinib demonstrated sustained clinical responses beyond 2 years, with 73% of responders alive and progression free. Zanubrutinib continued to demonstrate a favorable safety\/tolerability profile with the additional time on treatment. This trial was registered at www.clinicaltrials.gov as #NCT03846427.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010668","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T13:13:51Z","timestamp":1694178831000},"page":"6801-6811","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen","family":"Opat","sequence":"first","affiliation":[{"name":"1Monash Health and Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"2ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-0929","authenticated-orcid":false,"given":"Bei","family":"Hu","sequence":"additional","affiliation":[{"name":"3Levine Cancer Institute\/Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-1548","authenticated-orcid":false,"given":"Kim M.","family":"Linton","sequence":"additional","affiliation":[{"name":"4Division of Cancer Sciences, Manchester Cancer Research Centre, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-9730","authenticated-orcid":false,"given":"Pamela","family":"McKay","sequence":"additional","affiliation":[{"name":"5Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leitch","sequence":"additional","affiliation":[{"name":"6North Shore Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[{"name":"7Clinical Research Alliance, Lake Success, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"8IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"9The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Sun","sequence":"additional","affiliation":[{"name":"10Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sobieraj-Teague","sequence":"additional","affiliation":[{"name":"11Flinders Medical Centre, Bedford Park, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Browett","sequence":"additional","affiliation":[{"name":"12Auckland City Hospital, Grafton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[{"name":"13Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"14Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Saint-Louis, Hemato-oncology, Paris University Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirit","family":"Ardeshna","sequence":"additional","affiliation":[{"name":"15University College London Hospitals\/University College London Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6768-7175","authenticated-orcid":false,"given":"Fontanet","family":"Bijou","sequence":"additional","affiliation":[{"name":"16Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Walker","sequence":"additional","affiliation":[{"name":"17Peninsula Private Hospital, Ramsay Health Care, Frankston, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"18Olivia Newton-John Cancer Research Centre, Austin Health, Heidelberg, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5368-8975","authenticated-orcid":false,"given":"Shir-Jing","family":"Ho","sequence":"additional","affiliation":[{"name":"19St George Hospital, Kogarah, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-1377","authenticated-orcid":false,"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[{"name":"20Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Liang","sequence":"additional","affiliation":[{"name":"21BeiGene, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Xu","sequence":"additional","affiliation":[{"name":"22BeiGene, Ridgefield Park, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Tankersley","sequence":"additional","affiliation":[{"name":"23BeiGene, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[{"name":"24BeiGene, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melannie","family":"Co","sequence":"additional","affiliation":[{"name":"23BeiGene, San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"25Concord Repatriation General Hospital and University of Sydney, Concord, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"issue":"6","key":"2023112818513719000_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2023112818513719000_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann Lymphoma"},{"key":"2023112818513719000_bib3","unstructured":"National Comprehensive Cancer Network\n          . NCCN clinical practice guidelines in oncology: B-cell lymhomas, version 5. 2022. Accessed 14 February 2023. https:\/\/www.nccn.org\/guidelines\/category_1."},{"issue":"1","key":"2023112818513719000_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"5.5","key":"2023112818513719000_bib5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.6004\/jnccn.2022.5015","article-title":"Updates to the management of patients with relapsed or refractory indolent follicular and marginal zone lymphomas","volume":"20","author":"LaCasce","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"16","key":"2023112818513719000_bib6","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2023112818513719000_bib7","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"key":"2023112818513719000_bib8","unstructured":"Tam\n              CS\n            , WallisN, ZhangM, . Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib. Poster presented at: Lymphoma, Leukemia, and Myeloma (LLM) Congress; 18 to 22 October 2022; New York, NY. Accessed 14 February 2023. https:\/\/epostersonline.com\/llm2022\/poster\/p-040?view=true."},{"key":"2023112818513719000_bib9","unstructured":"European Medicines Agency\n          . Imbruvica (ibrutinib) SMPC. Accessed 14 February 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imbruvica."},{"issue":"17","key":"2023112818513719000_bib10","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J\u00a0Med Chem"},{"issue":"23","key":"2023112818513719000_bib11","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA Trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023112818513719000_bib12","article-title":"BRUKINSA (zanubrutinib). Prescribing information","year":"2023","journal-title":"BeiGene Ltd"},{"key":"2023112818513719000_bib13","unstructured":"BeiGene Ltd\n          . Press release: BeiGene announces Health Canada approval for BRUKINSA\u00ae (zanubrutinib) in relapsed or refractory marginal zone lymphoma. Accessed 14 February 2023. https:\/\/ir.beigene.com\/news\/beigene-announces-health-canada-approval-for-brukinsa-zanubrutinib-in-relapsed-or-refractory-marginal-zone-lymphoma\/e02c3862-c6f8-4588-bf56-6411bc77afbc\/."},{"key":"2023112818513719000_bib14","unstructured":"BeiGene Ltd\n          . Press release: BeiGene receives European Commission approval for BRUKINSA\u00ae (zanubrutinib) for the treatment of adults with marginal zone lymphoma. Accessed 14 February 2023. https:\/\/ir.beigene.com\/news\/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-adults-with-marginal\/66b2b907-4d3c-466f-836d-43e225f2a7b2\/."},{"issue":"27","key":"2023112818513719000_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"2023112818513719000_bib16","author":"Fayers","year":"2001","edition":"3rd ed."},{"issue":"10","key":"2023112818513719000_bib17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"14","key":"2023112818513719000_bib18","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/bloodadvances.2022009412","article-title":"Molecular associations of response to the new generation BTK inhibitor zanubrutinib in marginal zone lymphoma","volume":"7","author":"Tatarczuch","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2023112818513719000_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A\u00a0MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023112818513719000_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.2021.278755","article-title":"Marginal zone lymphoma: present status and future perspectives","volume":"107","author":"Cheah","year":"2022","journal-title":"Haematologica"},{"key":"2023112818513719000_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CMAR.S133291","article-title":"Management of relapsed\/refractory marginal zone lymphoma: focus on ibrutinib","volume":"10","author":"Denlinger","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"14","key":"2023112818513719000_bib22","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"2023112818513719000_bib23","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1200\/JCO.2020.38.15_suppl.8046","article-title":"MAGNIFY: phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"38","author":"Andorsky","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023112818513719000_bib24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/6801\/2110021\/blooda_adv-2023-010668-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/6801\/2110021\/blooda_adv-2023-010668-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T13:51:48Z","timestamp":1701179508000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/22\/6801\/497772\/Safety-and-efficacy-of-zanubrutinib-in-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":24,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010668","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]}}}